cjc-1295+ipamorelin CJC-1295 + Ipamorelin — Peptide Therapy Online CJC-1295 No DAC & Ipamorelin

While the study found no significant differences in the primary efficacy endpoint (time to first tolerated meal), the ipamorelin group showed reduced median time to first tolerated meal (25.3 hours versus 32.6 hours in placebo) and had fewer overall treatment-emergent adverse events (87.5% versus 94.8%)

10.1038/nn.4476 140 FunkK

Researchers trust PSPeptides for both their compounds and their BAC water because the quality, speed, and service are the same across the entire catalog

It can increase the efficiency of the oxidative phosphorylation process, which leads to increased energy production and better endurance